Vir Biotechnology Inc

NASDAQ:VIR   3:59:50 PM EDT
35.81
-2.89 (-7.47%)
Mergers / Acquisitions

GlaxoSmithKline Announces U.S. Govt Agreement To Buy Additional 600,000 Sotrovimab Doses

Published: 01/11/2022 12:19 GMT
Vir Biotechnology Inc (VIR) - Glaxosmithkline Plc - US Government Buys Additional 600,000 Sotrovimab Doses.
Gsk - 600,000 Additional Doses to Be Supplied to US Government for Distribution in Q1 2022, Enabling Further Access to Sotrovimab Nationwide.
Gsk: Total Number of Doses Secured to Date Through Binding Agreements to Approximately 1.7 Million Globally.
Gsk - Brings Total Number of Doses Secured to Date Through Binding Agreements to Approximately 1.7 Million Globally.
Gsk: Sotrovimab Retains Activity Against All Tested Sars-cov-2 Variants of Concern Including Delta and Omicron.
Gsk - Today's Agreement Also Includes Option for US Government to Purchase Further Additional Doses in Q2 of 2022.
Gsk: Gsk and Vir Expect to Manufacture Approximately 2 Million Doses Globally in First Half of 2022.
Gsk - Gsk and Vir Expect to Manufacture Approximately 2 Million Doses Globally in First Half of 2022 and Additional Doses in Second Half of Year.